July 19, 2017New England Journal of Medicine330 citationsOpen Access
View Full PaperANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Key Result
Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.
Structured PICO
Does evinacumab reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia?
P
Population
9 adults with homozygous familial hypercholesterolemia
I
Intervention
Evinacumab
O
Outcome
LDL cholesterol reduction at 4 weekssurrogate
Evinacumab substantially reduces LDL cholesterol in patients with homozygous familial hypercholesterolemia.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.